Dupilumab effect on pruritus neuro-mechanisms in patients with atopic dermatitis

Phase 1

• Conditions: Atopic Dermatitis; MedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders; Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

• Registration Number: EUCTR2020-003542-36-DE
• Lead Sponsor: Sanofi-aventis Recherche & Développement

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-16
• Last Update Posted: 17 August 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

For Atopic dermatitis patients
Male or female of =18 years of age inclusive, at the time of signing the informed consent form (ICF).
Diagnosed with moderate-to-severe chronic AD for at least 1 year before screening.
Eligible to be treated with dupilumab according to product monograph.
Pruritus lasting 6 or more weeks before baseline (Day 1).
Eczema Area and Severity Index (EASI) score =12 at baseline.
Pruritus numerical rating scale (NRS) =4 at baseline.
Investigator global assessment (IGA) score of =3 at screening (on the 0 to 4 scale) at baseline.
Atopic dermatitis active lesions on the upper limbs or lower limbs suitable for a skin biopsy without oozing, bleeding, or infection on upper limbs or trunk.
Patients with acute AD lesions as determined by Investigator’s judgment.
Stable treatment with non-prohibited medication or therapy during the study.

For Healthy participants
Male or female of =18 years of age inclusive, at the time of signing the ICF.
Certified as generally healthy by a comprehensive clinical assessment
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 4

Exclusion Criteria

For atopic dermatitis patients
Previous treatment with dupilumab stopped within 6 months of baseline due to inadequate response to dupilumab.
Skin conditions other than AD that can confound assessments in the opinion of theinvestigator.
Regular use (>2 visits per week) of a tanning booth/parlor within 4 weeks of the Screening Visit.
Severe concomitant illness(es) that, in the Investigator’s judgment, would adversely affect the patient’s participation in the study.
Patients with active tuberculosis (TB) or non-TB mycobacterial infection, or a history of incompletely treated TB unless it is well documented the participant has been adequately treated and can now start treatment with a biologic agent
Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drug within 2 weeks before the Screening Visit (Visit 1) or during the Screening Period.
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals,or antifungals within 2 weeks before the Screening Visit (Visit 1) or during the Screening Period.
Known or suspected immunodeficiency, including history of invasive opportunistic infections
Active malignancy or history of malignancy within 5 years before the Baseline Visit, except completely treated in situ carcinoma of the cervix and completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.
Ocular disorder that in the opinion of the Investigator could adversely affect the individual’s risk for study participation. Examples include, but are not limited to,individuals with a history of active cases of herpes keratitis, Sjogren’s syndrome, keratoconjunctivitis sicca or dry eye syndrome that require daily use of supplemental lubrication or individuals with ocular conditions that require the use of ocular corticosteroids or cyclosporine.
History of systemic hypersensitivity or anaphylaxis to dupilumab or any other biologic therapy, including any excipient.
Participant with any other medical or psychological condition including relevant laboratory or electrocardiogram abnormalities at screening

For healthy participants
Regular use (>2 visits per week) of a tanning booth/ parlor within 4 weeks of the Screening
Visit
Treatment with the following concomitant medications and procedures is prohibited within 4 weeks before the Screening Visit or 5 half-lives (whichever is longer) until EoS Visit:-
Topical medication.
Analgesics.
Immunomodulators.
Antidepressants.
Anti-anxiety drugs.
Any Type 2 immune disorders uncontrolled Type 2 diabetes mellitus, Type 1 diabetes mellitus, neuropathy or any other neurological disease.
Any concomitant illness(es) or conditions that, in the Investigator’s judgment, would
adversely affect the subject’s participation in the study or potentially affect any skin biopsy
related read out.
Positive test for immunoglobulin E (IgE) antibodies.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified